59 results about "Bacterial virulence" patented technology

The invention relates to, in part, secreted proteins of bacterial pathogens and methods for their use. More specifically, the invention provides in part several new common secreted proteins for A / E pathogens. In some embodiments of the invention, these polypeptides and nucleic acid molecules encoding these polypeptides, or portions thereof, are useful as vaccines, diagnostics, or drug screening tools for A / E pathogenic infections, or as reagents.

The present invention relates to a detection chip for performing gene detection to various vibrio and its detection and applications. The invention provides 16S rRNA sequences corresponding to each vibrio of vibrio anguillarum, vibrio harveyi, vibrio alginolyticus, vibrio parahaemolyticus, brilliant vibrio and Fisher vibrio; heat shock protein hsp60 probe sequence; virulence gene probe sequence; 16S rRNA forward primer sequence; 16S rRNA reverse primer sequence; heat shock protein hsp60 forward primer sequence; heat shock protein hsp60 reverse primer sequence; virulence gene forward primer sequence and virulence gene reverse primer sequence. The present invention has specific, sensitive and high-throughput features, can simultaneously detect six kinds of bacteria virulence genes, and the invention will effectively guide the production as an important disease early-warning detection method used in clinical diagnosis of aquatic animals.

Provided are antisense morpholino oligomers targeted against bacterial virulence factors such as genes that contribute to antibiotic resistance or biofilm formation, or genes associated with fatty acid biosynthesis, and related compositions and methods of using the oligomers and compositions, for instance, in the treatment of an infected mammalian subject.

This invention relates to composition and methods of employing said composition for treating or preventing microbial associated infections and diseases. More particularly the present invention relates to bacterial proteins, peptides and amino acids which are by-products of bacteria, in particular Lactobacillus and more specifically Lactobacillus strains GR-1 and RC-14, in compositions that can treat and prevent microbial-associated infections and diseases, by altering, for example, down-regulating, virulence properties of pathogenic organisms.

The present invention relates to methods of treating bacterial infection in a subject, degrading bacterial virulence factors, preventing bacteria from escaping phagosomes of neutrophils, and preventing bacteria from invading host cells, by use of an elastase.

The virulence of bacterial strains and in particular pathogenic bacteria which infect human is reduced by an agent which alters the bacteria's native level or activity of DNA methyltransferase (Dam). The agent causes an alteration in the bacteria's native level of methylation of adenine in a GATC tetranucleotide which inhibits virulence of the bacteria. Thus, compounds and formulations thereof which reduce bacterial virulence inhibit proliferation of bacteria and are useful in treating bacterial infections, particularly in humans.

The present invention relates to compounds and methods for the treatment of bacterial infections. Because their mechanism of action does not involve killing of bacteria or inhibiting their growth, the potential for these compounds to induce drug resistance in bacteria is minimized. Through inhibiting bacterial virulence, the present invention provides a novel means of treating bacterial infections.

A method for identifying antibacterial agents comprises depleting bacteria of a strain comprising a luxAB construct of Ca2+, incubating the Ca2+ depleted bacteria with an agent the antibacterial effect of which shall be determined, recording the light emitted by the bacteria upon addition of an aldehyde, the incubation being carried out at a temperature which is at least 10° C. higher than the temperature at which the light is emitted by the bacteria. Also disclosed are corresponding probes and antibacterial agents identified by the method.

Test kit for diagnosing periodontal disease in a patient by analysing a sample from the oral cavity of the patient. The test kit comprises at least a first detection assay for detection of a first substance originating from bacteria and at least a second detection assay for detection of a second substance originating from the immune or inflammatory system of the patient. Most preferably, said first substance is a bacterial virulence product such as e.g. arg-gingipain from Prophyromonas gingivalis, and said second substance is human neutrophil elastase.

The invention relates to antibacterial application of small molecular bacterial quorum sensing inhibitor Falcarindiol in the condition of no inhibition on bacteria growth concentration (subinhibitory concentration). The active compound has a broad-spectrum bacterial quorum sensing resistant activity, can inhibit bacterial virulence in subinhibitory concentration, reduces the harm of bacteria to the host, and can prevent and treat quorum sensing bacterial infections. The compound can play the role of inhibition of bacterial virulence in subinhibitory concentration, so that pressure for survival of pathogenic bacteria is not brought, drug resistance is not easy to produce, the antibacterial application of the small molecular bacterial quorum sensing inhibitor Falcarindiol in the condition of no inhibition on bacteria growth concentration (subinhibitory concentration) is different from application of killing bacteria and bacteria growth inhibition of other antibacterial agent, is also is different from the antibacterial application of bacteria growth inhibition of Falcarindiol with the bacteria concentration (the use final concentration is greater than the minimum bacteriostasis concentration), and is a new antibacterial application. The antibacterial application of the small molecular bacterial quorum sensing inhibitor Falcarindiol in the condition of no inhibition on bacteria growth concentration (subinhibitory concentration) has the advantages that: raw materials are easy to get, compound separation and purification are simple and easy to control, security is high, use concentration is low, and drug resistance is easy to produce, and the like, so that the Falcarindiol can be used in preparation of a new antibacterial agent.

A means for decreasing bacterial virulence in a mammal including man or in a plant by inhibition of the Type III secretion system at concentrations that do not prevent or substantially reduce bacterial growth comprises an N-substituted 7-quinolylmethyl amine, in particular one that is further substituted in 5- and 8-position on the quinoline ring. A corresponding therapeutic method and a pharmaceutical composition are also disclosed.

The application belongs to the field of medicine and discloses novel application of lotus plumule extracts, in particular to application of lotus plumule extracts in the preparation of inhibitory drugs for the quorum-sensing system. Experiments show that the lotus plumule extracts can inhibit the biological membrane of each of three species of Pseudomonas aeruginosa; that the lotus plumule extracts can inhibit the quorum-sensing system so as to decrease bacterial virulence and pathogenicity without inhibiting growth of bacteria, while bacterial drug resistance is rarely caused. Particularly all lotus plumule chloroform layer extract, lotus plumule ethyl acetate layer extract, lotus plumule total alkaloids extract and lotus plumule total flavones extract is as effective as or more effectivethan the positive drugs, furanone compounds, in inhibiting the biological membranes of Pseudomonas aeruginosa and drug-resistant Pseudomonas aeruginosa; it is indicated that the lotus plumule extracts provide good inhibition for both Pseudomonas aeruginosa and drug-resistant Pseudomonas aeruginosa.

Disclosed are bacterial virulence polypeptides and nucleic acid sequences (e.g., DNA) encoding such polypeptides, and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing such polypeptides to screen for antibacterial or bacteriostatic compounds.

The invention relates to application of myricanol in preparing a drug for resisting bacterial virulence. The structural formula of a compound 1 is shown in the description. The myricanol is a diarylheptanoids compound, and has a function of significantly inhibiting the secretion of virulence proteins of a salmonella type III secretion system (T3SS). The inhibitor does not inhibit the growth of salmonella, but inhibits the invasion of host cells by the salmonella, and therefore the compound can be used for preparing the drug for resisting the virulence of Gram-negative bacteria.

The present disclosure relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present disclosure provides compounds as therapeutic agents against bacterial infections (e.g., biofilms). The present disclosure also provides compounds as therapeutic agents in methods for treating pneumonia, methods for reducing bacterial virulence, methods for treating a bacterial wound infection, and methods for treating a urinary tract infection. The present disclosure also provides methods for treating a bacterial infection, wherein the bacterial infection has or is suspected of having an antibiotic-resistant bacteria. The present disclosure also provides surfaces coated with the chemical compounds disclosed herein.

The invention discloses a synthetic method of QseC ligand derivatives capable of inhibiting bacterial virulence and an application. The QseC ligand derivatives are bacterial membrane surface protein QseC ligands and can be specifically combined with the QseC ligands and be used for retroregulation of a qseC-qseB-fliC-flhD gene pathway, thereby inhibiting the release of bacterial pathogenic virulence factors, reducing the bacterial virulence and the invasiveness during the bacterial infection and further achieving the role of controlling the harm of the bacterial infection; however, the QseC ligand derivatives do not affect normal growth and reproduction of bacteria, thereby avoiding the initiation of bacterial drug resistance pressure. The QseC ligand derivatives have the advantages of good anti-bacterial effect, low toxicity, good stability and difficult drug resistance. The QseC ligand derivatives synthesized by the optimized synthetic method of the QseC ligands and the chemical synthetic method of the derivatives thereof can be used for preparing novel broad-spectrum antibacterial drugs with resistance to multi-drug-resistant bacteria infection.

The present invention relates to compounds and methods for the treatment of bacterial infections. The compounds and methods involve the disruption of the QseC signaling pathway which modulates the virulence of some bacteria. This methodology for treatment of bacterial infections reduces evolutionary pressure to develop resistance because the bacteria are not killed in the process.

Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.

The invention relates to bacterial infections, vaccines directed against those infections and bacterial vaccines. More particularly, the invention relates to vaccines directed against Streptococcus infections in pigs. Provided is a [Delta]FolT mutant of a bacterium having reduced capacity to transport folate, wherein the capacity has been reduced by functionally deleting folate transporter (FolT)function. The present invention provides a method to reduce virulence of a bacterium comprising reducing the capacity of the bacterium to transport folate.

Provided are antisense morpholino oligomers targeted against bacterial virulence factors such as genes that contribute to antibiotic resistance or biofilm formation, or genes associated with fatty acid biosynthesis, and related compositions and methods of using the oligomers and compositions, for instance, in the treatment of an infected mammalian subject.

The present disclosure relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present disclosure provides compounds as therapeutic agents against bacterial infections (e.g., biofilms). The present disclosure also provides compounds as therapeutic agents in methods for treating pneumonia, methods for reducing bacterial virulence, methods for treating a bacterial wound infection, and methods for treating a urinary tract infection. The present disclosure also provides methods for treating a bacterial infection, wherein the bacterial infection has or is suspected of having an antibiotic-resistant bacteria. The present disclosure also provides surfaces coated with the chemical compounds disclosed herein.

A method for identifying antibacterial agents comprises depleting bacteria of a strain comprising a luxAB construct of Ca2+, incubating the Ca2+ depleted bacteria with an agent the antibacterial effect of which shall be determined, recording the light emitted by the bacteria upon addition of an aldehyde, the incubation being carried out at a temperature which is at least 10° C. higher than the temperature at which the light is emitted by the bacteria. Also disclosed are corresponding probes and antibacterial agents identified by the method.

The invention provides bacterial quorum sensing inhibitors as well as a preparation method and an application thereof, and belongs to the technical field of medical chemistry. The bacterial quorum sensing inhibitors mainly comprise alpha-pyridoin derivatives with novel structures; research proves that the derivatives can remarkably reduce expression of related pathogenic factors and bacterial virulence in a range of not inhibiting growth of pathogenic bacteria, so that the derivatives can be used as the bacterial quorum sensing inhibitors for preventing and controlling bacterial infection of aquorum sensing system. Meanwhile, the preparation method of the compounds is simple, reaction conditions are mild, raw materials are cheap and easily available, the various compounds with brand-new structure can be prepared and obtained rapidly on a large scale, and the method has good economy and large-scale industrial production value.

The present invention relates to compounds and methods for the treatment of bacterial infections. Because their mechanism of action does not involve killing of bacteria or inhibiting their growth, the potential for these compounds to induce drug resistance in bacteria is minimized. Through inhibiting bacterial virulence, the present invention provides a novel means of treating bacterial infections.

Compounds that inhibit bacterial virulence factors from the mono-ADP-ribosyltransferase (mART) family of toxins have been identified that are not toxic to cells or the producing bacterial pathogen. These compounds have great potential as antivirulence agents for treating many bacterial infections and disease states.

The invention discloses an antisense deoxyribozyme-DNAzyme23. The antisense deoxyribozyme disclosed by the invention adopts an effector molecule RNAIII in the staphylococcus aureus agr quorum-sensing system as a target spot, does not affect the growth state of the bacterium, can effectively block an agr signaling pathway, can significantly weaken the bacterial virulence and particularly can significantly reduce the pathogenicity of methicillin-resistant staphylococcus aureus. The antisense deoxyribozyme has the advantages of high specificity, low toxicity, safety and difficulty in inducing the increase of bacterial drug resistance and the like.

Novel rapamycin analogues and methods for their production with FKBP and / or MIP inhibitory activity with reduced mTOR inhibitory activity with therapeutic potential e.g. as bacterial virulence inhibitors.